TISSUE PLASMINOGEN ACTIVATOR MARKET ANALYSIS
Global Tissue Plasminogen Activator Market: Key Developments
In July 2021, Boehringer Ingelheim GmbH, a worldwide pharmaceutical company, announced its plan to initiate Phase III part of its Phase II/III TRISTARDS clinical study of alteplase to treat COVID-19 patients with acute respiratory distress syndrome (ARDS). The drug demonstrated a promising safety and effectiveness profile in an interim review of the study, which has completed the exploratory open-label Phase IIb phase with 62 patients.
Tissue Plasminogen Activator Market Report Snapshots
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowWant to Buy a Report but have a Limited Budget?
We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount
Reliability and Reputation
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India :